EA015846B1 - 2-[5-бром-4-(4-циклопропилнафталин-1-ил)-4н-[1,2,4]триазол-3-илсульфанил]уксусная кислота и ее метиловый эфир - Google Patents

2-[5-бром-4-(4-циклопропилнафталин-1-ил)-4н-[1,2,4]триазол-3-илсульфанил]уксусная кислота и ее метиловый эфир Download PDF

Info

Publication number
EA015846B1
EA015846B1 EA200901186A EA200901186A EA015846B1 EA 015846 B1 EA015846 B1 EA 015846B1 EA 200901186 A EA200901186 A EA 200901186A EA 200901186 A EA200901186 A EA 200901186A EA 015846 B1 EA015846 B1 EA 015846B1
Authority
EA
Eurasian Patent Office
Prior art keywords
triazol
ylsulfanyl
bromo
compounds
mmol
Prior art date
Application number
EA200901186A
Other languages
English (en)
Russian (ru)
Other versions
EA200901186A1 (ru
Inventor
Жан-Люк Жирарде
Юнг-Хио Кох
Марта Де Ла Роза
Эсмир Гуник
Чжи Хун
Стенли Лэнг
Хонг Воо Ким
Original Assignee
Ардеа Байосайенсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36000576&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA015846(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ардеа Байосайенсиз, Инк. filed Critical Ардеа Байосайенсиз, Инк.
Publication of EA200901186A1 publication Critical patent/EA200901186A1/ru
Publication of EA015846B1 publication Critical patent/EA015846B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Road Signs Or Road Markings (AREA)
  • Pens And Brushes (AREA)
  • Enzymes And Modification Thereof (AREA)
EA200901186A 2004-08-25 2005-08-25 2-[5-бром-4-(4-циклопропилнафталин-1-ил)-4н-[1,2,4]триазол-3-илсульфанил]уксусная кислота и ее метиловый эфир EA015846B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60421904P 2004-08-25 2004-08-25
US60422004P 2004-08-25 2004-08-25
US68635105P 2005-05-31 2005-05-31

Publications (2)

Publication Number Publication Date
EA200901186A1 EA200901186A1 (ru) 2010-04-30
EA015846B1 true EA015846B1 (ru) 2011-12-30

Family

ID=36000576

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200901186A EA015846B1 (ru) 2004-08-25 2005-08-25 2-[5-бром-4-(4-циклопропилнафталин-1-ил)-4н-[1,2,4]триазол-3-илсульфанил]уксусная кислота и ее метиловый эфир
EA200700488A EA014737B1 (ru) 2004-08-25 2005-08-25 S-ТРИАЗОЛИЛ-α-МЕРКАПТОАЦЕТАНИЛИДЫ В КАЧЕСТВЕ ИНГИБИТОРА ОБРАТНОЙ ТРАНСКРИПТАЗЫ ВИЧ

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200700488A EA014737B1 (ru) 2004-08-25 2005-08-25 S-ТРИАЗОЛИЛ-α-МЕРКАПТОАЦЕТАНИЛИДЫ В КАЧЕСТВЕ ИНГИБИТОРА ОБРАТНОЙ ТРАНСКРИПТАЗЫ ВИЧ

Country Status (31)

Country Link
US (8) US7947721B2 (enExample)
EP (5) EP2433633A1 (enExample)
JP (2) JP4952943B2 (enExample)
KR (1) KR101241716B1 (enExample)
CN (2) CN101083987B (enExample)
AT (2) ATE540677T1 (enExample)
AU (2) AU2005280130C9 (enExample)
BR (2) BRPI0514630B8 (enExample)
CA (1) CA2578068C (enExample)
CY (2) CY1112221T1 (enExample)
DK (1) DK2135608T3 (enExample)
EA (2) EA015846B1 (enExample)
EC (1) ECSP077322A (enExample)
ES (2) ES2380604T3 (enExample)
FR (1) FR16C0031I2 (enExample)
HR (1) HRP20130075T1 (enExample)
HU (1) HUS1600034I1 (enExample)
IL (3) IL181523A (enExample)
IN (1) IN2014CN03762A (enExample)
LT (1) LTC2135608I2 (enExample)
LU (1) LU93169I2 (enExample)
ME (1) ME01512B (enExample)
MX (1) MX2007002236A (enExample)
NL (1) NL300825I2 (enExample)
NZ (2) NZ581376A (enExample)
PL (1) PL2135608T3 (enExample)
PT (1) PT2135608E (enExample)
RS (1) RS52632B (enExample)
SG (2) SG185992A1 (enExample)
SI (1) SI2135608T1 (enExample)
WO (1) WO2006026356A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2666549C2 (ru) * 2012-07-03 2018-09-18 Ардеа Биосайнсиз, Инк. Получение 2-(5-бром-4-(4-циклопропилнафталин-1-ил)-4h-1,2,4-триазол-3-илтио)уксусной кислоты

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE540677T1 (de) * 2004-08-25 2012-01-15 Ardea Biosciences Inc S-triazolyl alpha mercaptoacetanilide als hemmer der reversen transkriptase von hiv
WO2007050087A1 (en) * 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
WO2008145562A1 (en) 2007-05-30 2008-12-04 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
WO2009030996A1 (en) * 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Triazole compounds as toll-like receptor (tlr) agonists
WO2009070740A2 (en) * 2007-11-27 2009-06-04 Ardea Biosciences Inc. Novel compounds and compositions and methods of use
KR101294872B1 (ko) 2008-09-04 2013-08-08 아디아 바이오사이언스즈 인크. 요산 수치를 조절하기 위한 화합물, 조성물 및 이들의 사용 방법
US8173690B2 (en) 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8242154B2 (en) 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
WO2010048593A1 (en) * 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( l-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triazol-3-ylthio) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
WO2010048592A1 (en) * 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
CA2760940A1 (en) 2009-05-20 2010-11-25 Ardea Biosciences, Inc. Methods of modulating uric acid levels
CN102040546B (zh) * 2009-10-10 2014-10-15 台州市华南医化有限公司 一种4-环丙基-1-异硫氰基萘的制备方法及中间体4-环丙基-1-萘甲醛肟/卤化物
MX2012007925A (es) * 2010-01-08 2012-08-03 Ardea Biosciences Inc Formas polimorficas, cristalinas y de mesofase de 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-ilti o)acetato de sodio, y usos de las mismas.
WO2011126852A2 (en) 2010-03-30 2011-10-13 Ardea Biosciences, Inc. Treatment of gout
PL2582683T3 (pl) 2010-06-15 2018-08-31 Ardea Biosciences, Inc. Leczenie dny moczanowej i hiperurykemii
BR112012032193A2 (pt) 2010-06-16 2019-09-24 Ardea Biosciences Inc composto, composiçoes e métodos de uso de feniltioacetato
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
CN101899013B (zh) * 2010-07-12 2012-07-25 山东大学 2-(2-取代芳基-2h-1,2,4-三唑-3-巯基)乙酰胺衍生物及其制备方法与应用
CN103249417A (zh) * 2010-10-15 2013-08-14 阿迪亚生命科学公司 用于治疗高尿酸血症及相关疾病的方法
MX2013007505A (es) 2010-12-30 2013-08-01 Ardea Biosciences Inc Formas polimorficas de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1 -il)-4h-1,2,4-triazol-3-iltio)acetico y usos de los mismos.
ES2704233T3 (es) 2011-11-03 2019-03-15 Ardea Biosciences Inc Compuesto de piridina 3,4-di-sustituido, procedimientos de uso y composiciones que comprenden el mismo
CN105263913B (zh) * 2013-06-14 2017-12-15 广东东阳光药业有限公司 硫代1,2,4‑三唑衍生物及其制备方法
CN103524440B (zh) * 2013-10-15 2015-09-09 苏州鹏旭医药科技有限公司 痛风治疗药Lesinurad的制备方法及Lesinurad中间体
JP6470761B2 (ja) * 2013-11-22 2019-02-13 クリスタル ファーマテック カンパニー、リミテッドＣｒｙｓｔａｌ Ｐｈａｒｍａｔｅｃｈ Ｃｏ．， Ｌｔｄ． レシヌラドおよびそのナトリウム塩の結晶形態
CN104557748A (zh) * 2014-01-25 2015-04-29 广东东阳光药业有限公司 硫代-1,2,4-三唑衍生物的新的固体形态
CN105315218A (zh) * 2014-07-17 2016-02-10 天津药物研究院 一种制备lesinurad中间体1-萘基三唑硫酮的方法
CN104326993B (zh) * 2014-10-27 2016-08-17 张远强 一种硝基取代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104341361B (zh) * 2014-10-27 2017-01-11 张远强 一种腈基取代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104326998B (zh) * 2014-10-27 2016-08-17 张远强 苯基取代的三氮唑丙二酸类化合物、其制备方法及用途
CN104311498B (zh) * 2014-10-27 2016-04-06 张远强 烷氧基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104327000B (zh) * 2014-10-27 2016-08-17 张远强 苯基取代的三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104341362B (zh) * 2014-10-27 2016-07-13 张远强 三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104370842B (zh) * 2014-10-27 2016-07-13 张远强 苯基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
CN104370841B (zh) * 2014-10-27 2016-07-13 张远强 三氮唑亚磺酰丙二酸类化合物、其制备方法及用途
CN104341363B (zh) * 2014-10-27 2016-08-17 张远强 一种硝基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途
EP3112334A1 (en) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Process for manufacturing 1-cyclopropyl-naphthalenes
CN104987311A (zh) * 2015-06-30 2015-10-21 安徽万邦医药科技有限公司 一种[4-(4-环丙基萘-1-基)-5-硝基- 4h-[1,2,4]三唑-3-基硫烷基]-乙酸乙酯的制备方法及其中间体(5-硝基-4h-[1,2,4]三唑-3-基硫基)-乙酸乙酯
CN105017168A (zh) * 2015-07-01 2015-11-04 安徽万邦医药科技有限公司 一种[5-溴-4-(4-环丙基萘-1-基)-4h-[1,2,4]三唑-3-基硫烷基]-乙酸甲酯的新制备方法
CN105153056A (zh) * 2015-07-01 2015-12-16 安徽万邦医药科技有限公司 一种[5-溴-4-(4-环丙基萘-1-基)-4h-[1,2,4]三唑-3-基硫烷基]-乙酸甲酯的新制备方法
WO2017036884A1 (en) 2015-08-28 2017-03-09 Sandoz Ag A lesinurad, free form / lesinurad ethyl ester co-crystal
CN105566237B (zh) * 2016-03-01 2018-05-18 山东大学 一种治疗痛风的三唑巯乙酸类化合物的制备方法
DK3473617T3 (da) 2016-06-17 2022-11-28 Medshine Discovery Inc Halogeneret forbindelse og aksiale, chirale isomerer deraf
EP3281941B1 (en) 2016-08-11 2019-07-24 Zentiva K.S. Process for preparing 2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid
EP3372592A1 (en) 2017-03-07 2018-09-12 Zentiva, k.s. Solid forms of lesinurad amine salts
US10351537B2 (en) * 2017-03-10 2019-07-16 Apotex Inc. Processes for the preparation of lesinurad and intermediates thereof
EP3315494A1 (en) 2017-04-19 2018-05-02 Química Sintética, S.A. Amorphous form of lesinurad and processes for its preparation
CN108947919B (zh) 2017-05-17 2023-05-02 上海奥博生物医药股份有限公司 一种抗痛风药Lesinurad的新型制备方法及其关键中间体
WO2019001325A1 (zh) * 2017-06-28 2019-01-03 苏州科睿思制药有限公司 雷西纳得的晶型xv及其制备方法
EP3498697A1 (en) 2017-12-12 2019-06-19 Química Sintética, S.A. Novel salts and polymorphs of lesinurad
JP7728864B2 (ja) 2021-05-28 2025-08-25 住友化学株式会社 シクロアルキルブロミドの製造方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2225860C2 (ru) * 1998-12-25 2004-03-20 Шионоги & Ко., Лтд. Ароматические гетероциклические соединения, обладающие активностью в отношении вич-интегразы
WO2004030611A2 (en) * 2002-08-23 2004-04-15 Ribapharm Inc. Non-nucleoside reverse transcriptase inhibitors

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2009A (en) * 1841-03-18 Improvement in machines for boring war-rockets
US2008A (en) * 1841-03-18 Gas-lamp eok conducting gas pkom ah elevated buhner to one below it
US226186A (en) 1880-04-06 Car-coupling
US2006A (en) * 1841-03-16 Clamp for crimping leather
JPS5641637B2 (enExample) 1973-11-26 1981-09-29
US6832996B2 (en) * 1995-06-07 2004-12-21 Arthrocare Corporation Electrosurgical systems and methods for treating tissue
JPH07215940A (ja) 1994-01-27 1995-08-15 Torii Yakuhin Kk 抗ウイルス活性を有する化合物
US6245817B1 (en) * 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
CA2251368A1 (en) 1997-02-14 1998-08-20 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
JPH10243033A (ja) * 1997-02-28 1998-09-11 Oki Electric Ind Co Ltd 復調装置
BRPI9909191B8 (pt) * 1998-03-27 2021-07-06 Janssen Pharmaceutica Nv derivados de pirimidina inibidores do hiv, seu uso e composição farmacêutica que os compreende
AU755997B2 (en) 1998-11-12 2003-01-02 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
US6414147B1 (en) * 1998-12-23 2002-07-02 Neurogen Corporation 2-amino-9-alkylpurines: GABA brain receptor ligands
US6593077B2 (en) * 1999-03-22 2003-07-15 Special Materials Research And Technology, Inc. Method of making thin films dielectrics using a process for room temperature wet chemical growth of SiO based oxides on a substrate
EP1363877A2 (en) 2001-03-02 2003-11-26 SmithKline Beecham Corporation Benzophenones as inhibitors of reverse transcriptase
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
JP2005529923A (ja) 2002-05-13 2005-10-06 イーライ・リリー・アンド・カンパニー 肥満および糖尿病の治療におけるメラニン凝集ホルモンアンタゴニストとして使用するための多環式化合物
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
EA011164B1 (ru) 2003-02-07 2009-02-27 Янссен Фармацевтика Н. В. Производные пиримидина для профилактики вич-инфекции
MXPA06002069A (es) 2003-09-25 2006-05-19 Janssen Pharmaceutica Nv Derivados de purina que inhiben la replicacion del vih.
US20080031901A1 (en) * 2004-09-24 2008-02-07 Abbott Laboratories Sustained release monoeximic formulations of opioid and nonopioid analgesics
US7517998B2 (en) 2004-06-01 2009-04-14 Boehringer Ingelheim International Gmbh Non nucleoside reverse transcriptase inhibitors
ATE540677T1 (de) 2004-08-25 2012-01-15 Ardea Biosciences Inc S-triazolyl alpha mercaptoacetanilide als hemmer der reversen transkriptase von hiv
WO2007050087A1 (en) * 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
WO2009070740A2 (en) * 2007-11-27 2009-06-04 Ardea Biosciences Inc. Novel compounds and compositions and methods of use
WO2010048593A1 (en) 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( l-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triazol-3-ylthio) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
WO2010048592A1 (en) 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
TWM377707U (en) * 2009-09-16 2010-04-01 Nat Energy Technology Co Ltd Assembly of power supply

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2225860C2 (ru) * 1998-12-25 2004-03-20 Шионоги & Ко., Лтд. Ароматические гетероциклические соединения, обладающие активностью в отношении вич-интегразы
WO2004030611A2 (en) * 2002-08-23 2004-04-15 Ribapharm Inc. Non-nucleoside reverse transcriptase inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2666549C2 (ru) * 2012-07-03 2018-09-18 Ардеа Биосайнсиз, Инк. Получение 2-(5-бром-4-(4-циклопропилнафталин-1-ил)-4h-1,2,4-триазол-3-илтио)уксусной кислоты

Also Published As

Publication number Publication date
HRP20130075T1 (hr) 2013-02-28
BRPI0514630B8 (pt) 2021-05-25
CN101817793A (zh) 2010-09-01
AU2009217458A8 (en) 2009-10-29
US8946273B2 (en) 2015-02-03
EA014737B1 (ru) 2011-02-28
DK2135608T3 (da) 2012-01-23
EP2402011B1 (en) 2012-11-14
IL201546A (en) 2013-10-31
EP2135608B8 (en) 2012-03-21
US20150094284A1 (en) 2015-04-02
ES2380604T3 (es) 2012-05-16
US8003681B2 (en) 2011-08-23
US8252828B2 (en) 2012-08-28
ME01512B (me) 2014-04-20
SG185992A1 (en) 2012-12-28
BRPI0514630B1 (pt) 2020-09-15
US20100081827A1 (en) 2010-04-01
AU2005280130B2 (en) 2009-09-10
IL181523A0 (en) 2007-07-04
CY2016028I1 (el) 2016-12-14
EP2402011A1 (en) 2012-01-04
CN101083987A (zh) 2007-12-05
US7947721B2 (en) 2011-05-24
CA2578068C (en) 2011-08-09
ATE528001T1 (de) 2011-10-15
BRPI0520870B1 (pt) 2020-11-10
JP2008510828A (ja) 2008-04-10
AU2009217458A1 (en) 2009-10-15
AU2005280130C9 (en) 2010-03-04
LTPA2016024I1 (lt) 2016-09-12
US20100069645A1 (en) 2010-03-18
EP2433633A1 (en) 2012-03-28
JP2012077088A (ja) 2012-04-19
CN101083987B (zh) 2011-01-26
EP1789039B1 (en) 2012-01-11
HUS1600034I1 (hu) 2016-09-28
JP5457472B2 (ja) 2014-04-02
MX2007002236A (es) 2007-07-09
ES2374773T3 (es) 2012-02-21
EP1789039A2 (en) 2007-05-30
CN101817793B (zh) 2014-01-08
NZ553534A (en) 2010-10-29
CA2578068A1 (en) 2006-03-09
US20110313157A1 (en) 2011-12-22
EP2609917A1 (en) 2013-07-03
AU2005280130A1 (en) 2006-03-09
KR101241716B1 (ko) 2013-03-08
NZ581376A (en) 2011-05-27
SI2135608T1 (sl) 2012-03-30
NL300825I2 (enExample) 2017-01-24
SG155246A1 (en) 2009-09-30
US20120283301A1 (en) 2012-11-08
LU93169I2 (fr) 2016-10-10
CY1112221T1 (el) 2015-12-09
ECSP077322A (es) 2007-04-26
WO2006026356A2 (en) 2006-03-09
US20180002296A1 (en) 2018-01-04
CY2016028I2 (el) 2016-12-14
KR20070054694A (ko) 2007-05-29
IL219131A0 (en) 2012-06-28
EA200700488A1 (ru) 2007-08-31
EP2135608B1 (en) 2011-10-12
HK1133582A1 (en) 2010-04-01
EP2135608A1 (en) 2009-12-23
JP4952943B2 (ja) 2012-06-13
BRPI0520870B8 (pt) 2021-05-25
US20110190491A1 (en) 2011-08-04
LTC2135608I2 (lt) 2017-07-25
RS52632B (sr) 2013-06-28
US8481581B2 (en) 2013-07-09
FR16C0031I1 (enExample) 2016-09-23
FR16C0031I2 (fr) 2017-03-31
IL181523A (en) 2013-12-31
BRPI0514630A (pt) 2008-06-17
EP1789039A4 (en) 2009-08-05
AU2005280130C1 (en) 2010-02-18
PT2135608E (pt) 2012-01-13
US20100267724A2 (en) 2010-10-21
AU2009217458B2 (en) 2009-11-19
ATE540677T1 (de) 2012-01-15
US20080176850A1 (en) 2008-07-24
WO2006026356A3 (en) 2006-08-10
IN2014CN03762A (enExample) 2015-09-25
PL2135608T3 (pl) 2012-07-31
EA200901186A1 (ru) 2010-04-30

Similar Documents

Publication Publication Date Title
EA015846B1 (ru) 2-[5-бром-4-(4-циклопропилнафталин-1-ил)-4н-[1,2,4]триазол-3-илсульфанил]уксусная кислота и ее метиловый эфир
TWI703147B (zh) 用於治療胃腸發炎性疾病之jak抑制劑化合物之前藥
TWI843506B (zh) 橋聯三環胺甲醯基吡啶酮化合物及其用途
NO314936B1 (no) 4,4-disubstituerte-3,4-dihydro-2(1H)-kinazolinoner, farmasöytiske sammensetninger, preparater og farmasöytiske sett til behandling av HIV-infeksjon, samt anvendelse av bestemte kinazolinoner for fremstilling av etfarmasöytisk preparat
JP2003512375A (ja) Ｈｉｖ逆転写酵素阻害剤としての縮合ナフチリジン
EA023009B1 (ru) Ингибитор hcv сериновой протеазы, полученный из макроциклического пролина, и фармацевтическая композиция, предназначенная для лечения вирусной инфекции
JPH06506199A (ja) 抗ウイルス性ヌクレオシドコンビネーション
HUT58069A (en) Process for producing aminobenzodiazepines and pharmaceutical compositions comprising same
TW201120042A (en) N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
US20120225889A1 (en) Use of macrocyclic lactone derivatives for the treatment of inflammatory disorders
HUP0303818A2 (hu) HIV reverz transzkriptáz inhibitorként alkalmazható triciklikus vegyületek és ezeket tartalmazó gyógyszerkészítmények
JP2000309598A (ja) 多剤結合型新規化合物、その製造法および用途
HUT61468A (en) Process for producing pharmaceutical compositions against human retrovirus and comprising xanthine derivatives as active ingredient
JPH04305578A (ja) ベンゾジアゼピン、その製造法、及び薬剤としての利用
JP4887305B2 (ja) Ｈｉｖの治療に有用な化合物
US8513214B2 (en) C4′-substituted-2-deoxyadenosine analogs and methods of treating HIV
JP2016540776A (ja) 分枝鎖非環式ヌクレオシドホスホン酸エステルならびにその合成法および使用
JP2008526713A5 (enExample)
JP2911956B2 (ja) ５，１１―ジヒドロ―６Ｈ―ピリド［２，３―ｂ］［１，４］ベンゾジアゼピン―６―オン及び―チオン並びに該化合物のＡＩＤＳの予防又は治療における使用法
US20190218216A1 (en) Pyridopyrimidines derivatives compounds
WO2018181102A1 (ja) ヌクレオシド誘導体又はその塩、及びそれを含む医薬組成物
JP5174660B2 (ja) Ｈｉｖインヒビターとしての１’−［２’−３’−ジデオキシ−３’ｃ−（ヒドロキシメチル）−ベータ−ｄ−エリトロペントフラノシル］シトシン誘導体
KR20000053122A (ko) Ｈｉｖ 프로테아제 억제제로 유용한 1-(3-아미노인다졸-5-일)-3-페닐메틸-시클릭 우레아
JP2001503429A (ja) （４ｒ，５ｓ，６ｓ，７ｒ）―ヘキサヒドロ―１―［５―（３―アミノインダゾール）メチル］―３―ブチル―５，６―ジヒドロキシ―４，７―ビス［フェニルメチル］―２ｈ―１，３―ジアゼピン―２―オンおよびそのｈｉｖプロテアーゼ阻害剤としての使用
WO2022132918A9 (en) Method for treating or inhibiting cytomegalovirus infection using small molecules targeting protein phosphatase 1

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM